I am originally from Wichita, KS and currently reside in Lee’s Summit, MO. I came to Kansas City to attend Rockhurst University and graduated in December of 2002 with a Bachelor of Science in Chemistry. I began my graduate education here at the Medical Center in the fall of 2004. After completing the first year of IGPBS core study, I decided to join the laboratory of Dr. Curtis Klaassen.
Research Interests
My research interests involve the study of the transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2), particularly in the liver, the major metabolic center in the body. In unstressed conditions, Nrf2 is bound and sequestered in the cytosol by Keap1. Oxidative stress and some compounds faciliitate Nrf2 avoidance of Keap1 and translocation of Nrf2 into the nucleus. Once in the nucleus, Nrf2 will bind to the Antioxidant Response Element (ARE), which then promotes the transcription of many detoxification and cytoprotective enzymes, such as heme oxygenase-1, NADPH quinone reducatase-1, and glutathione-S-transferases.
Whereas there is little doubt that the induction of cytoprotective genes, such as Nqo1 and Gsts, via Nrf2 activation, is important in the prevention of hepatic injury, I am also interested in the effect of Nrf2 on pharmacokinetics. Because Nrf2 activtation results in induction of genes that could increase elimination of certain xenobiotics, pharmacokinetic alterations meditated by Nrf2 should also be considered as a means of protection against oxidative injury.
Selected Publications
Tanaka Y, Aleksunes LM, Goedken M, Chuan C, Reisman SA, Manautou JE, and Klaassen CD. Protective role of NF-E2-Related Factor 2 (Nrf2) in iron nitrilotriacetate (Fe-NTA)-induced renal oxidative damage in mice, 2008, Toxicol Appl Pharmacol, accepted, in press.
Reisman SA, Aleksunes LM, and Klaassen CD. Oleanolic acid induces antioxidant processes by facilitating nuclear accumulation of nuclear factor erythroid-2 related factor 2 (Nrf2), 2008, in preparation.
Reisman SA, Buckley DB, Tanaka Y, and Klaassen CD. CDDO-Im protects against hepatotoxicants through activation of Nrf2 and induction of antioxidant genes, 2008, in preparation.
Scott Reisman
Department of Pharmacology, Toxicology, and Therapeutics
The University of Kansas Medical Center
MS1018
3901 Rainbow Boulevard
Kansas City, KS 66160
Phone: (913) 588-9248
Fax: (913)588-7501
E-Mail: sreisman@kumc.edu
Updated 9/5/08
©
The University of Kansas Medical Center